Advances in metal-carbene complexes as potent anti-cancer agents.

This critical review is an updated survey of metal-carbenes as potential anticancer chemotherapeutics. We report on the recent advances in the discovery of N-heterocyclic carbenes, acyclic diamino carbenes and abnormal NHCs associated with metals from groups 10 and 11 that displayed antiproliferative activity and emphasize, when possible, their molecular target(s) and their mechanism of action.

[1]  C. Cannon,et al.  The medicinal applications of imidazolium carbene-metal complexes. , 2009, Chemical reviews.

[2]  S. Patil,et al.  Synthesis, Cytotoxicity and Antibacterial Studies of p-Methoxybenzyl-Substituted and Benzyl-Substituted N-Heterocyclic Carbene-Silver Complexes , 2010 .

[3]  S. Berners‐Price,et al.  Dinuclear gold(I) complexes of bridging bidentate carbene ligands: synthesis, structure and spectroscopic characterisation. , 2004, Dalton transactions.

[4]  S. Wölfl,et al.  Benzimidazol-2-ylidene gold(I) complexes are thioredoxin reductase inhibitors with multiple antitumor properties. , 2010, Journal of medicinal chemistry.

[5]  J. Alfaro,et al.  Biomedical properties of a series of ruthenium-N-heterocyclic carbene complexes based on oxidant activity in vitro and assessment in vivo of biosafety in zebrafish embryos. , 2010, Zebrafish.

[6]  C. Cannon,et al.  Synthesis, stability, and antimicrobial studies of electronically tuned silver acetate N-heterocyclic carbenes. , 2008, Journal of medicinal chemistry.

[7]  A. Gautier,et al.  Metal-NHC complexes: a survey of anti-cancer properties. , 2009, Dalton transactions.

[8]  C. Marzano,et al.  Copper complexes as anticancer agents. , 2009, Anti-cancer agents in medicinal chemistry.

[9]  D. Carrez,et al.  Cytostatic Activity of 1,10‐Phenanthroline Derivatives Generated by the Clip‐Phen Strategy , 2005, Chembiochem : a European journal of chemical biology.

[10]  C. Leung,et al.  Cyclometalated gold(III) complexes with N-heterocyclic carbene ligands as topoisomerase I poisons. , 2010, Chemical communications.

[11]  Laure Eloy,et al.  Investigation of a series of silver-N-heterocyclic carbenes as antibacterial agents: activity, synergistic effects, and cytotoxicity. , 2011, Chemistry.

[12]  I. Ott.  On the medicinal chemistry of gold complexes as anticancer drugs , 2009 .

[13]  K. Fritz-Wolf,et al.  Undressing of phosphine gold(I) complexes as irreversible inhibitors of human disulfide reductases. , 2006, Angewandte Chemie.

[14]  S. Patil,et al.  Synthesis, cytotoxicity and antibacterial studies of symmetrically and non‐symmetrically benzyl‐ or p‐cyanobenzyl‐substituted N‐Heterocyclic carbene–silver complexes , 2010 .

[15]  D. Enders,et al.  Organocatalysis by N-heterocyclic carbenes. , 2007, Chemical reviews.

[16]  N. Metzler‐Nolte,et al.  The Synthesis of Ruthenium and Rhodium Complexes with Functionalized N‐Heterocyclic Carbenes and Their Use in Solid Phase Peptide Synthesis , 2008 .

[17]  A. Balch,et al.  Palladium and platinum complex resulting from the addition of hydrazine to coordinated isocyanide , 1970 .

[18]  P. Dyson,et al.  Metal-based antitumour drugs in the post-genomic era: what comes next? , 2011, Dalton transactions.

[19]  S. Gilbertson,et al.  Development of building blocks for the synthesis of N-heterocyclic carbene ligands. , 2005, Organic letters.

[20]  Shonagh Walker,et al.  The status of platinum anticancer drugs in the clinic and in clinical trials. , 2010, Dalton transactions.

[21]  A. Ditto,et al.  Anticancer Activity of Ag(I) N-Heterocyclic Carbene Complexes Derived from 4,5-Dichloro-1H-Imidazole , 2008, Metal-based drugs.

[22]  M. J. Hannon.  Metal-based anticancer drugs: From a past anchored in platinum chemistry to a post-genomic future of diverse chemistry and biology , 2007 .

[23]  W. Herrmann.  N-heterocyclic carbenes: a new concept in organometallic catalysis. , 2002 .

[24]  P. Escribá,et al.  Synthesis and mass spectroscopy kinetics of a novel ternary copper(II) complex with cytotoxic activity against cancer cells. , 2007, Journal of inorganic biochemistry.

[25]  A. Casini,et al.  Thioredoxin reductase, an emerging target for anticancer metallodrugs , 2011 .

[26]  C. Che,et al.  Anticancer Cyclometalated [AuIIIm(C∧N∧C)mL]n+ Compounds: Synthesis and Cytotoxic Properties , 2006 .

[27]  Bernhard Spingler,et al.  [(C3H4N2)2Au]Cl--a bis protic gold(I)-NHC. , 2011, Dalton transactions.

[28]  J. Steer,et al.  Luminescence studies of the intracellular distribution of a dinuclear gold(I) N-heterocyclic carbene complex. , 2006, Angewandte Chemie.

[29]  M. Khan,et al.  A palladium Chugaev carbene complex as a modular, air-stable catalyst for Suzuki-Miyaura cross-coupling reactions , 2005 .

[30]  Bernhard Lippert,et al.  Cisplatin : chemistry and biochemistry of a leading anticancer drug , 2006 .

[31]  J. Mague,et al.  Large-bite bis(phosphite) ligand containing mesocyclic thioether moieties: synthesis, reactivity, group 11 (Cu(I), Au(I)) metal complexes and anticancer activity studies on a human cervical cancer (HeLa) cell line. , 2008, Dalton transactions.

[32]  S. Patil,et al.  Synthesis, Cytotoxicity and Antibacterial Studies of Novel Symmetrically and Nonsymmetrically 4-(Methoxycarbonyl)benzyl-Substituted N-Heterocyclic Carbene–Silver Acetate Complexes , 2010 .

[33]  K. Öfele.  1,3-Dimethyl-4-imidazolinyliden-(2)-pentacarbonylchrom ein neuer übergangsmetall-carben-komplex , 1968 .

[34]  V. Gandin,et al.  In vitro antitumor activity of the water soluble copper(I) complexes bearing the tris(hydroxymethyl)phosphine ligand. , 2008, Journal of medicinal chemistry.

[35]  H. Raubenheimer,et al.  A cytotoxic bis(carbene)gold(I) complex of ferrocenyl complexes: synthesis and structural characterisation , 2008 .

[36]  James L. Hickey,et al.  Cationic, linear Au(I) N-heterocyclic carbene complexes: synthesis, structure and anti-mitochondrial activity. , 2006, Dalton transactions.

[37]  S. Patil,et al.  Synthesis, Cytotoxicity and Antibacterial Studies of Novel Symmetrically and Non-Symmetrically p-Nitrobenzyl-Substituted N-Heterocyclic Carbene–Silver(I) Acetate Complexes , 2011 .

[38]  G. Puleo,et al.  Direct functionalisation of group 10 N-heterocyclic carbene complexes for diversity enhancement. , 2011, Chemical communications.

[39]  B. Meunier,et al.  Preparation of the New Bis(phenanthroline) Ligand "Clip-Phen" and Evaluation of the Nuclease Activity of the Corresponding Copper Complex. , 1998, Inorganic chemistry.

[40]  C. Che,et al.  Therapeutic applications of gold complexes: lipophilic gold(III) cations and gold(I) complexes for anti-cancer treatment. , 2011, Chemical communications.

[41]  N. Oppenheimer,et al.  Copper-dependent cleavage of DNA by bleomycin. , 1987, Biochemistry.

[42]  L. Cavallo,et al.  (NHC)Copper(I)-catalyzed [3+2] cycloaddition of azides and mono- or disubstituted alkynes. , 2006, Chemistry.

[43]  S. Patil,et al.  Novel benzyl-substituted N-heterocyclic carbene-silver acetate complexes: synthesis, cytotoxicity and antibacterial studies. , 2011, Metallomics : integrated biometal science.

[44]  P. Ghosh,et al.  Design of nickel chelates of tetradentate N-heterocyclic carbenes with subdued cytotoxicity , 2009 .

[45]  A. Vessières,et al.  Metal complex SERMs (selective oestrogen receptor modulators). The influence of different metal units on breast cancer cell antiproliferative effects. , 2006, Dalton transactions.

[46]  S. Berners‐Price,et al.  Mitochondria-targeted chemotherapeutics: the rational design of gold(I) N-heterocyclic carbene complexes that are selectively toxic to cancer cells and target protein selenols in preference to thiols. , 2008, Journal of the American Chemical Society.

[47]  A. Gautier,et al.  A platinum Chugaev carbene complex as a potent anticancer agent. , 2011, Chemical communications.

[48]  James L. Hickey,et al.  Synthesis and structural characterisation of linear Au(I) N-heterocyclic carbene complexes: New analogues of the Au(I) phosphine drug Auranofin , 2005 .

[49]  L. Tschugájeff,et al.  Über Die Hydrazin-Carbylamin-Komplexe des Platins , 1925 .

[50]  R. Schibli,et al.  Metal chelating systems synthesized using the copper(I) catalyzed azide-alkyne cycloaddition. , 2010, Dalton transactions.

[51]  Richard L. Harlow,et al.  A stable crystalline carbene , 1991 .

[52]  S. Berners‐Price,et al.  Gold compounds as therapeutic agents for human diseases. , 2011, Metallomics : integrated biometal science.

[53]  A. Riches,et al.  Cytotoxicity of gold(I) N-heterocyclic carbene complexes assessed by using human tumor cell lines. , 2011, Chemistry.

[54]  D. T. Walz,et al.  Oral gold. Antiarthritic properties of alkylphosphinegold coordination complexes. , 1972, Journal of medicinal chemistry.

[55]  J. Schellens,et al.  A Phase I and Pharmacological Study with Imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent , 2004, Clinical Cancer Research.

[56]  S. Berners‐Price,et al.  Mitochondrial permeability transition induced by dinuclear gold(I)-carbene complexes: potential new antimitochondrial antitumour agents. , 2004, Journal of inorganic biochemistry.

[57]  M. Panzner,et al.  Synthesis and anticancer properties of gold(I) and silver(I) N-heterocyclic carbene complexes , 2011 .

[58]  A. Gautier,et al.  Toxicity of copper(I)-NHC complexes against human tumor cells: induction of cell cycle arrest, apoptosis, and DNA cleavage. , 2009, Chemistry.

[59]  P. Retailleau,et al.  N-heterocyclic carbene-amine Pt(II) complexes, a new chemical space for the development of platinum-based anticancer drugs. , 2010, Journal of medicinal chemistry.

[60]  S. Nolan,et al.  Carbenes : Synthesis, properties, and organometallic chemistry , 2009 .

[61]  S. Berners‐Price.  Activating platinum anticancer complexes with visible light. , 2011, Angewandte Chemie.

[62]  A. Slawin,et al.  A N-heterocyclic carbene gold hydroxide complex: a golden synthon. , 2010, Chemical communications.

[63]  N. Metzler‐Nolte,et al.  Organometallic peptide NHC complexes of Cp∗Rh(III) and arene Ru(II) moieties from l-thiazolylalanine , 2011 .

[64]  A. Lorber,et al.  Screening trial with the coordinated gold compound auranofin using mouse lymphocyte leukemia P388. , 1981, Cancer research.

[65]  B. Tinant,et al.  Synthetic and structural studies of NHC–Pt(dvtms) complexes and their application as alkene hydrosilylation catalysts (NHC = N-heterocyclic carbene, dvtms = divinyltetramethylsiloxane) , 2005 .

[66]  W. Berger,et al.  KP1019, A New Redox‐Active Anticancer Agent – Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients , 2008, Chemistry & biodiversity.

[67]  N. Bottini,et al.  Gold(I)-mediated inhibition of protein tyrosine phosphatases: a detailed in vitro and cellular study. , 2008, Journal of medicinal chemistry.

[68]  S. Nolan,et al.  Synthesis and characterization of gold(I) N-heterocyclic carbene complexes bearing biologically compatible moieties , 2006 .

[69]  C. Che,et al.  Luminescent cyclometalated platinum(II) complexes containing N-heterocyclic carbene ligands with potent in vitro and in vivo anti-cancer properties accumulate in cytoplasmic structures of cancer cells , 2011 .

[70]  Amitabha Bhattacharyya,et al.  Coinage metal-N-heterocyclic carbene complexes. , 2009, Chemical reviews.

[71]  BARNETT ROSENBERG,et al.  Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode , 1965, Nature.

[72]  G. Gasser,et al.  Organometallic Anticancer Compounds , 2010, Journal of medicinal chemistry.

[73]  W. Hung,et al.  Preparation and characterization of amino-linked heterocyclic carbene palladium, gold, and silver complexes and their use as anticancer agents that act by triggering apoptotic cell death. , 2011, Journal of medicinal chemistry.

[74]  Nicolas Marion,et al.  N-heterocyclic carbenes as organocatalysts. , 2007, Angewandte Chemie.

[75]  H. Wanzlick,et al.  Direct Synthesis of a Mercury Salt‐Carbene Complex , 1968 .

[76]  A. Rubinstein,et al.  The use of in vivo zebrafish assays in drug toxicity screening , 2009 .

[77]  Dulal Panda,et al.  Anticancer and antimicrobial metallopharmaceutical agents based on palladium, gold, and silver N-heterocyclic carbene complexes. , 2007, Journal of the American Chemical Society.

[78]  S. Berners‐Price,et al.  Targeting the mitochondrial cell death pathway with gold compounds , 2007 .

[79]  M. Harding,et al.  Antitumour bis(cyclopentadienyl) metal complexes: titanocene and molybdocene dichloride and derivatives. , 2007, Dalton transactions.

[80]  S. Crooke,et al.  Evaluation of the in vivo antitumor activity and in vitro cytotoxic properties of auranofin, a coordinated gold compound, in murine tumor models. , 1985, Cancer research.